Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway

<table>Cost-effectiveness acceptability curves reflecting the probability of cost-effectiveness for etoricoxib, celecoxib (200 &amp; 400 mg), diclofenac, and naproxen at a followup of 1 year, 5 years, and 30 years (base-case scenario).</table>

International Journal of Rheumatology

fig2

Figure 2

Figure 2: Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway 